NEA, 5AM back a $50M play to steer gene therapies to the clinic at Akouos — the latest startup in hearing
Hearing is getting to be a trendy R&D topic in biotech.
Eight months after putting together a $7.5 million seed round and lining up AAV gene therapy technology out of Massachusetts Eye and Ear and Lonza, the startup Akouos has come back with a fast $50 million A round designed to get them through their preclinical phase and up to the threshold of their first human study.
Initially focused on a rare genetic mutation that leads to deafness in newborns, Akouos CEO Manny Simons tells me that the biotech has its eyes on a lineup of monogenetic ailments related to hearing. And they’re looking to restore hearing with a pipeline of therapies, eventually expanding into broader causes of hearing loss for an aging society.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.